Kymera Therapeutics (KYMR)

• Market cap: $2.63B
• 1 day: 3.88%
• 5 days: -3.58%
• 1 month: -7.70%
• 3 months: -18.34%
• 6 months: 30.03%
• Year to date: 60.39%
• 1 year: 65.96%
• 5 years: 22.25%
• 10 years: 22.25%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Employees: 184

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

95% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 19

61% more capital invested

Capital invested by funds: $2.03B [Q2] → $3.26B (+$1.23B) [Q3]

11% more funds holding

Funds holding: 157 [Q2] → 175 (+18) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 7 (+0) [Q3]

2.7% less ownership

Funds ownership: 110.86% [Q2] → 108.16% (-2.7%) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 63

27% less call options, than puts

Call options by funds: $2.82M | Put options by funds: $3.88M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $49 21% upside
• Avg. target: $58 42% upside
• High target: $74 82% upside

9 analyst ratings

• positive: 7 78%
• neutral: 2 22%
• negative: 0 0%

BTIG Jeet Mukherjee 0% 1-year accuracy 0 / 2 met price target	48% upside $60	Buy Initiated	10 Dec 2024
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	35% upside $55	Market Perform Initiated	6 Dec 2024
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	40% upside $57	Overweight Upgraded	2 Dec 2024
Stephens & Co. Sudan Loganathan 26% 1-year accuracy 5 / 19 met price target	60% upside $65	Overweight Initiated	18 Nov 2024
Morgan Stanley James Quigley 0 / 0 met price target	21% upside $49	Equal-Weight Maintained	6 Nov 2024